Development of new forms of interventions for diastolic heart failure (HFpEF) remains a challenging task. The aim: Assessing the effect of combining erythropoietin and sildenafil on the left ventricle “LV” functions and morphometry in NG-nitro-L-arginine methyl ester (L-NAME)-induced HFpEF model in rats. Method: Forty-eight female albino rats were randomly assigned to one of six treatment groups: “C” (Control), “L” (L-NAME-treated), “L+M” (L-NAME+milrinone-treated), “L+S” (L-NAME+sildenafil-treated), “L+E” (L-NAME+erythropoietin-treated), and “L+S+E” (L-NAME+sildenafil+erythropoietin-treated). Assessment was done by morphometric examination, LV ejection fraction (LVEF) and fraction of shortening (LVFS)], ECG changes, and mean time to peak tension (TPT) and to complete relaxation (TCR) of isometric contraction of LV muscle strip stimulated by single (TPT-S & TCR-S) and by repeated pulses (TPT-R & TCR-R), respectively. Results: L-NAME resulted in cardiac dysfunction with significant reduction in the mean “LVEF” and “LVFS”, and prolonged both the mean “TPT-R” and “TCR-R”. Milrinone and sildenafil treatment significantly corrected these parameters. In addition, erythropoietin significantly ameliorated “LVEF” and “LVFS” and shortened “TPT-S”. Similarly, “sildenafil+erythropoietin” treatment significantly corrected the measured parameters; however, they were insignificantly different from that of sildenafil only treatment. Morphometrically, sildenafil treatment resulted in significant but partial improvement in L-NAME-induced myocardial injury. Meanwhile, erythropoietin treatment showed more improvement. Moreover, combination treatment showed the best histologic picture in all of the treated groups. Conclusion: Sildenafil was able to improve cardiac functions mainly by accelerating diastolic relaxation. Addition of erythropoietin to sildenafil improved its cytoprotective effect.
Alalkamy, E. (2018). ERYTHROPOIETIN HAS AN ADDITIVE CYTOPROTECTIVE AND BENEFICIAL EFFECT TO SILDENAFIL IN A MODEL OF DIASTOLIC HEART FAILURE IN RATS. Al-Azhar Journal of Pharmaceutical Sciences, 58(2), 1-18. doi: 10.21608/ajps.2018.46636
MLA
Essam Alalkamy. "ERYTHROPOIETIN HAS AN ADDITIVE CYTOPROTECTIVE AND BENEFICIAL EFFECT TO SILDENAFIL IN A MODEL OF DIASTOLIC HEART FAILURE IN RATS". Al-Azhar Journal of Pharmaceutical Sciences, 58, 2, 2018, 1-18. doi: 10.21608/ajps.2018.46636
HARVARD
Alalkamy, E. (2018). 'ERYTHROPOIETIN HAS AN ADDITIVE CYTOPROTECTIVE AND BENEFICIAL EFFECT TO SILDENAFIL IN A MODEL OF DIASTOLIC HEART FAILURE IN RATS', Al-Azhar Journal of Pharmaceutical Sciences, 58(2), pp. 1-18. doi: 10.21608/ajps.2018.46636
VANCOUVER
Alalkamy, E. ERYTHROPOIETIN HAS AN ADDITIVE CYTOPROTECTIVE AND BENEFICIAL EFFECT TO SILDENAFIL IN A MODEL OF DIASTOLIC HEART FAILURE IN RATS. Al-Azhar Journal of Pharmaceutical Sciences, 2018; 58(2): 1-18. doi: 10.21608/ajps.2018.46636
)
View on SCiNiTO